Pulmonx has developed the Zephyr® Endobronchial Valve Therapy, a minimally invasive treatment for severe COPD/emphysema.
Visit https://uspatients.pulmonx.com/ for more. The one-time procedure is done during a simple bronchoscopy that require no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced.* Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath. Some patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.**
The Zephyr® Valves were approved by the FDA in June 2018. Since 2007, more than 25,000 patients have been treated with the Zephyr® Valve worldwide**. The Zephyr® Valve is included in emphysema treatment guidelines issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE). Important Safety Information: The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. Complications of treatment can include but are not limited to pneumothorax (tear in the lung), worsening of COPD symptoms, hemoptysis, pneumonia, and, in rare cases, death. The Zephyr® Valve is contraindicated in patients who have not quit smoking or are allergic to Nitinol (nickel-titanium). Please talk with your physician about other contraindications, warnings, precautions, and adverse events. Only a trained physician can decide whether a particular patient is an appropriate candidate for treatment with the Zephyr® Valve.
*The exact number of valves placed is based on physician discretion and patient anatomy.
**Criner G et al. Am J Respir Crit Care Med. 2018; 198 (9): 1151–1164.
03/12/2026
Living with severe COPD/emphysema doesn’t mean giving up hope.
Join our upcoming webinar and hear from a Zephyr Valve recipient who will share their personal story - from navigating daily challenges to finding a treatment option that helped them move forward.
This conversation is about learning, encouragement, and hearing from someone who truly understands what living with severe emphysema can feel like. It’s a chance to explore what may be possible and feel supported along the way.
📅 Wednesday, March 18
⏰ 11:00AM PST / 2:00PM EST
💙 Save your spot: https://bit.ly/46yZpNU
Speaker is a volunteer and not paid by Pulmonx Corporation. Results may vary.
03/03/2026
Living with severe COPD/emphysema can make everyday life feel overwhelming, but you’re not alone.
Join our upcoming webinar and hear directly from a Zephyr Valve recipient who will share their personal journey living with severe COPD/emphysema and how they took steps to better manage their condition.
You’ll have the chance to:
✔️ Hear a real patient story
✔️ Learn what the Zephyr Valve experience can be like
✔️ Ask questions in a supportive, patient-focused setting
📅 Wednesday, March 18
⏰ 11:00 AM PST /2:00 PM EST
👉 Register here: https://bit.ly/46yZpNU
Speaker is a volunteer and not paid by Pulmonx Corporation. Results may vary.
02/24/2026
More than 40,000 people worldwide have already been treated with Zephyr Valves.
Find a treatment center near you and take the next step toward breathing easier: https://bit.ly/4kYQzOq
Have questions about the Zephyr Valve procedure or whether you may qualify?
Our Zephyr Valve Care Team is here to help - from answering questions, providing you resources, and connecting you with a Zephyr Valve center in your area, and more.
Call 800-986-4197 to speak to our customer care team!
Severe COPD/emphysema left Bob struggling for breath. Saddling his horse, riding competitively, even walking uphill became overwhelming. The activities that once defined his life in northern Colorado slowly slipped away.
Following treatment with Zephyr Valves, Bob is breathing easier and back in the saddle. He’s riding, competing, and spending meaningful time with his horse, Marley, doing what he loves most again.
For Bob, better breathing meant getting his life back.
Endobronchial valve therapy (EBV) is not a cure for COPD, but for Bob, it helped him breathe easier, allowing him to get back on his horse.
02/03/2026
Guidelines now suggest that people who are screened for lung cancer should also be screened for COPD at the same time.1
Studies show, when people undergoing lung cancer screening are checked for COPD, 57% are diagnosed with the disease. Early detection gives you a chance to act sooner.2
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2025 Report. Available from: http://goldcopd.org.
2. Ruparel M, Quaife SL, Dickson JL, et al. Ann Am Thorac Soc. 2020;17(7):869-878. doi:10.1513/AnnalsATS.201911-857OC
01/27/2026
Start the year with a breath of fresh air!
Take our quick quiz to see if you might be a candidate for Zephyr Valves — a minimally invasive treatment that may help people get back to doing what they love.
What you eat matters, especially when living with COPD. We hope these simple nutrition tips to support better breathing are helpful. Take a look at the full article here for more info: https://bit.ly/4rBdZ0k
01/13/2026
Did you know that you do not need to be on continuous oxygen to qualify for Zephyr Valves?
Many patients treated with Zephyr Valves weren’t on oxygen therapy before the procedure. In one clinical study, 64% of patients did not require continuous oxygen at the time of treatment. 1
Learn how Zephyr Valves may help people with severe COPD/emphysema breathe easier and get back to doing what they love. https://bit.ly/4rDCBph
Results can vary depending on individual health and lung condition.
1. Criner, GJ, et al. Am J Respir Crit Care Med, 2018; 198(9), 1151-1164
01/06/2026
If you’re living with severe COPD/emphysema, every breath can feel like a challenge. Zephyr Endobronchial Valves are a proven treatment designed to help those who meet the eligibilty criteria.1
They work by letting trapped air escape from your lungs, which can reduce shortness of breath and help your lungs function better. Many patients report feeling more energetic, less breathless, and able to do more of the activities they enjoy.1
Be the first to know and let us send you an email when Pulmonx posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Pulmonx has developed the Zephyr Endobronchial Valve Therapy, a minimally invasive treatment for COPD/emphysema. The one-time procedure is done during a simple bronchoscopy that require no cutting or incisions. During the procedure, on average 4 tiny valves are placed in the airways to block off the diseased parts of the lung which allows trapped air to escape until the lobe is reduced. Reducing hyperinflation and preventing air from getting trapped in the diseased parts of the lung allows the healthier parts of the lungs to expand and take in more air. This results in patients being able to breathe easier and have less shortness of breath.1 Patients treated report immediate relief and the ability to go back to doing everyday tasks with ease.
The Zephyr Valves were approved by the FDA in June 2018. Since 2007, more than 15,000 patients have been treated with the Zephyr Valve worldwide. The Zephyr Valve is included in emphysema treatment guidelines issued by leading health organizations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK’s National Institute for Health and Care Excellence (NICE).
Complications of the Zephyr Endobronchial Valve treatment can include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.1
1. Criner G et al AM J Resp Crit Care Med 2018, Published on 22-May-2018 as 10.1164/rccm.201803-0590OC
Brief Statement: The Pulmonx Zephyr®Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valve is contraindicated for: Patients for whom bronchoscopic procedures are contraindicated; those with evidence of active pulmonary infection; known allergies to Nitinol (nickel-titanium) or its constituent metals (nickel or titanium); known allergies to silicone, or with large bullae encompassing greater than 30% of either lung; Patients who have not quit smoking. The Zephyr Valve should be used with caution and only after careful consideration in treating patients with: Prior lung transplant, LVRS, median sternotomy, or lobectomy; Congestive heart failure or recent myocardial infarction; FEV1
